title: Treatment of non-genotype 1 hepatitis C virus patients.
abstract: The HCV genotype will remain an important, independent pre-treatment predictor of virological response. While direct acting antivirals (DAA) will improve in the coming months the rates of virological response in patients with HCV-1, the development of DAAs effective against other HCV genotypes is at an earlier stage. Therefore, Peg-Interferon and Ribavirin will continue to be used in the near future as standard treatment in these patients. In this manuscript, we will discuss highly debated aspects related to non-1 HCV genotypes. First of all, the predictive role of IL28B genetic variation, secondarily specific aspects related to HCV-4. In the final part, we will highlight potential differences between HCV-2 and HCV-3. Indeed, despite the fact that HCV-2 and HCV-3 have been evaluated together in the majority of studies, HCV-3 patients achieve lower rates of virological response as compared to HCV-2. Whether a genotype individualized treatment may increase virologic response is the object of current investigations.
authors: Liver Unit, IRCCS, Hospital Casa Sollievo della Sofferenza, 71013, San Giovanni Rotondo, Italy. a.mangia@tin.it
authors: Alessandra
authors: A
authors: Mangia
authors: Leonardo
authors: L
authors: Mottola
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics*; D006526:Hepatitis C / Q000188:drug therapy* / Q000235:genetics / Q000821:virology; D006801:Humans; D007372:Interferons; D007378:Interleukins / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D012367:RNA, Viral / Q000187:drug effects; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D007372:Interferons; D007378:Interleukins; D012367:RNA, Viral; C000624353:interferon-lambda, human; D000095022:Interferon Lambda